SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:2162 4011
 

Sökning: L773:2162 4011 > (2015-2019) > Cancer vaccine base...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004842naa a2200469 4500
001oai:DiVA.org:uu-346362
003SwePub
008180316s2018 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3463622 URI
0247 a https://doi.org/10.1080/2162402X.2017.13972502 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Fotaki, Grammatikiu Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk immunologi4 aut0 (Swepub:uu)grafo260
2451 0a Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models
264 1c 2018
338 a electronic2 rdacarrier
520 a Autologous patient-derived dendritic cells (DCs) modified ex vivo to present tumor-associated antigens (TAAs) are frequently used as cancer vaccines. However, apart from the stringent logistics in producing DCs on a patient basis, accumulating evidence indicate that ex vivo engineered DCs are poor in migration and in fact do not directly present TAA epitopes to naïve T cells in vivo. Instead, it is proposed that bystander host DCs take up material from vaccine-DCs, migrate and subsequently initiate antitumor T-cell responses. We used mouse models to examine the possibility of using pro-inflammatory allogeneic DCs (alloDCs) to activate host DCs and enable them to promote antigen-specific T-cell immunity. We found that alloDCs were able to initiate host DC activation and migration to draining lymph node leading to T-cell activation. The pro-inflammatory milieu created by alloDCs also led to recruitment of NK cells and neutrophils at the site of injection. Vaccination with alloDCs combined with Ad5M(gp100), an infection-enhanced adenovirus encoding the human melanoma-associated antigen gp100 resulted in generation of CD8+ T cells with a T-cell receptor (TCR) specific for the gp10025-33 epitope (gp100-TCR+). Ad5M(gp100)-alloDC vaccination in combination with transfer of gp100-specific pmel-1 T cells resulted in prolonged survival of B16-F10 melanoma-bearing mice and altered the composition of the tumor microenvironment (TME). We hereby propose that alloDCs together with TAA- or neoepitope-encoding Ad5M can become an “off-the-shelf” cancer vaccine, which can reverse the TME-induced immunosuppression and induce host cellular anti-tumor immune responses in patients without the need of a time-consuming preparation step of autologous DCs.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Immunologi inom det medicinska området0 (SwePub)301102 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Immunology in the medical area0 (SwePub)301102 hsv//eng
653 a adjuvants
653 a Allogeneic dendritic cells
653 a cell-based immunotherapy
653 a tumor microenvironment
653 a tumor-associated antigen
7001 a Jin, Chuan,d 1986-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)chuji162
7001 a Kerzeli, Iliana Kyriakiu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)iliky579
7001 a Ramachandran, Mohanraj,d 1988-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)mohra272
7001 a Martikainen, Minttu-Mariau Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)minma327
7001 a Karlsson-Parra, Alexu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab,Immunicum AB, Gothenburg4 aut0 (Swepub:uu)aka12694
7001 a Yu, Di,d 1985-u Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)diayu422
7001 a Essand, Magnusu Uppsala universitet,Klinisk immunologi,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)magnessa
7102 a Uppsala universitetb Science for Life Laboratory, SciLifeLab4 org
7730 t Oncoimmunologyg 7:3q 7:3x 2162-4011x 2162-402X
8564 u https://doi.org/10.1080/2162402X.2017.1397250y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1191184/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-346362
8564 8u https://doi.org/10.1080/2162402X.2017.1397250

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy